Compass Pathways’ Phase IIb psilocybin trial shows reduced depression symptoms

UK biotech Compass Pathways revealed this morning that they reached the primary endpoint in a Phase IIb clinical trial of psilocybin therapy.

Category Press Release
Country United Kingdom

Companies Featured

COMPASS Pathways
COMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.